Rate My Professor Noelyn Hung

In research, Dr. Hung co-leads the Slatter and Hung Laboratory focusing on molecular pathogenesis, translating cell fate knowledge from precancerous lesions, cancers, placentas, and autoimmune conditions to clinical settings. Notable contributions include demonstrating human papillomavirus (HPV) as a key factor in placental complications during pregnancy via the Otago Placental Study (OPuS), developing glioblastoma subtyping based on telomere maintenance mechanisms for the New Zealand Brain Tumour Study, and exploring telomere pathways in uterine cancer to predict outcomes. Her biotechnology experience encompasses leading over 500 pharmacokinetic/pharmacodynamic (PK/PD) phase 1 and 2 clinical studies as Principal Investigator. Key recent publications encompass "Δ133p53 isoform enhances TLR4 function to promote tumour growth" (Carcinogenesis, 2025), "Oral docetaxel plus encequidar: A phase 1 clinical trial" (Cancer Chemotherapy & Pharmacology, 2024), "A sensitive assay for unbound docetaxel using ultrafiltration plus HPLC-MS" (Pharmaceutics, 2024), "Oral docetaxel plus encequidar: A pharmacokinetic model" (Journal of Pharmacokinetics & Pharmacodynamics, 2024), and "Optimal sample selection applied to information rich, dense data" (Journal of Pharmacokinetics & Pharmacodynamics, 2024). Her work underscores the regulation of cell death, survival, and growth across reproductive, oncologic, and autoimmune contexts.